(1) UPPSALA, SWEDEN - LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients. "We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid as being an innovative technology platform," said Monica Wallter, CEO of LIDDS. Liproca Depot, which comprises the NanoZolid technology combined with an antiandrogen drug (2-hydroxyflutamide) injected into the prostate, met both the primary and secondary endpoints in the study. Efficacy was shown by a maintained PSA decrease over 6 months, lower prostate volume and unchanged or improved MRI results. No hormonal side effects were shown. LIDDS concludes that Liproca Depot can be a new potential local treatment that is effective in controlling cancer for intermediate risk patients under "Active Surveillance". The manuscript has the title "Liproca Depot - A new antiandrogen treatment for active surveillance patients" and is planned to be published on the European Urology Focus webpage during February.